Open Access
Editorial
Table 1
Mechanistic axes of GLP-1RA action relevant to orthopaedics.
| Study | Mechanistic axes | Principal effects | Comments |
|---|---|---|---|
| Luo et al. [1] | ↓ Sclerostin → ↑ Wnt/β-catenin; RANKL/OPG modulation; Anti-inflammatory cytokine shift | Enhances osteoblastogenesis, reduces osteoclastogenesis, and promotes a healing milieu | Preclinical studies: improved bone mass/strength; relevant in osteoporosis and fracture healing |
| Spence et al. [4] | Weight loss & metabolic improvements | Reduces joint load, lowers complication risk | Indirect musculoskeletal benefit, but weight loss may reduce BMD |
| Anastasilakis et al. [8] | Dual/triple incretin agonists; Amylin analogues; ActRII antagonists | Stronger anabolic potential; bone & muscle preservation | Novel therapies may improve skeletal outcomes |
| Nance [19] | Chondrocyte/cartilage homeostasis | May slow osteoarthritis progression, improve joint function | Preclinical chondroprotection, relevant in knee osteoarthritis |
OPG: osteoprotegerin; BMD: bone mineral density; ActRII: Activin type II receptor.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.